INTRODUCTION
Parasitic diseases are a serious health problem, especially in developing countries. Virtually all people are threatened to some extent by eukaryotic parasites of different species, so the design of new effective anti-parasite drugs is a task of outstanding importance. Additional difficulties emerge due to the parasites’ rapid development of resistance and therefore novel drugs affecting previously unexplored targets are needed. Among these targets, protein kinases are very promising due to the existing knowledge base accumulated during studies of human kinases. Extensive target analysis is needed before planning experimental work.
Design of new kinase inhibitors is a widely studied problem in drug discovery, and interest in various kinases as drug targets is growing. Such inhibitors are most widely studied in the context of cancer treatment (Zhang et al. Reference Zhang, Yang and Gray2009a), but new applications of this approach regularly emerge, including anti-bacterial (Kurosu and Begari, Reference Kurosu and Begari2010), anti-protozoal (Canduri et al. Reference Canduri, Perez, Caceres and de Azevedo2007) and anti-parasitic (Liotta and Siekierka, Reference Liotta and Siekierka2010) drug development. Nevertheless, the potential of many parasite kinases for therapeutic intervention has not been studied thoroughly.
Glycogen synthase kinase 3 (GSK-3) is a conserved eukaryotic enzyme participating in different cellular pathways. The first identified function of the kinase was phosphorylation of glycogen synthase in rabbit skeletal muscle (Embi et al. Reference Embi, Rylatt and Cohen1980), and a number of different targets were then found for this kinase in the human organism (Rayasam et al. Reference Rayasam, Tulasi, Sodhi, Davis and Ray2009). Inhibition of GSK-3 can be used during the treatment of Alzheimer's disease (Avila et al. Reference Avila, Wandosell and Hernández2010), type 2 diabetes (Henriksen and Dokken, Reference Henriksen and Dokken2006), shock and inflammation (Dugo et al. Reference Dugo, Collin and Thiemermann2007). One of the most important functions of GSK-3 inhibition is the regulation of the cellular signalling pathway Wnt, which leads to the stabilization of β-catenin and gene expression (Wu and Pan, Reference Wu and Pan2009). Despite the activation of this pathway in many cancer conditions, systemic pharmacological inhibition of GSK-3 does not lead to carcinogenesis in healthy subjects (Patel and Woodgett, Reference Patel and Woodgett2008) and may even have anti-cancer effects due to inhibition of the insulin pathway that is activated in certain types of cancer (Ougolkov and Billadeau, Reference Ougolkov and Billadeau2006). There is much evidence that at least 2 independent pools of GSK-3 exist in cells (Frame and Zheleva, Reference Frame and Zheleva2006), one being involved in the Wnt pathway and another one regulated by Akt/PKB in the glycogen metabolism pathway.
Although GSK-3 possesses the common kinase fold (Fig. 1) and function, it has a number of specific features. The kinase shows a strong preference for pre-phosphorylated (primed) substrates bearing a phosphate group in position (N+4), where N is the number of the residue phosphorylated by GSK-3. The kinase is constitutively active and is usually regulated by autoinhibition following the Akt/PKB-mediated phosphorylation of Ser21 (GSK-3α) or Ser9 (GSK-3β) which occupies the priming phosphate binding site and prevents substrate binding (Dajani et al. Reference Dajani, Fraser, Roe, Young, Good, Dale and Pearl2001). The kinase is activated by Tyr216 (residue numbering is according to human GSK-3β sequence if not stated otherwise) autophosphorylation shortly after expression, but this effect is unidirectional, and activity of the kinase is not regulated by the reversible phosphorylation of this residue (Lochhead et al. Reference Lochhead, Kinstrie, Sibbet, Rawjee, Morrice and Cleghon2006). Another route of GSK-3 inhibition is phosphorylation of Ser389 by p38 MAP kinase (Thornton et al. Reference Thornton, Pedraza-Alva, Deng, Wood, Aronshtam, Clements, Sabio, Davis, Matthews, Doble and Rincon2008).
Structure of human GSK-3β residues 35–383 (PDB ID 1UV5 (Meijer et al. 2003)). Cartoon representation is coded by colours: N-terminal region (up to residue 55) – red; non-specific parts of the kinase domain (residues 56–340) – magenta; glycine loop – yellow; loop and helix C – white; hinge – cyan; activation loop – blue; axin-binding site – greenblue; C-terminal region (residues 341–383) – tan. Conserved residues are purple (Lys85 and Asp200 – common for all kinases), orange (Arg96, Arg180, Lys 205 – priming phosphate-binding site) and white (Tyr216 – phosphorylation site at activation loop).
Two isoforms of GSK-3, α and β, are present in the human organism along with GSK-3β2, a splice variant of the β-isoform (Rayasam et al. Reference Rayasam, Tulasi, Sodhi, Davis and Ray2009). The difference between isoforms is subtle in the catalytic domain and more pronounced in the N-terminal region, where the α-isoform has a large glycine-rich insertion. The isoforms possess different expression profiles and biological function (Liang and Chuang, Reference Liang and Chuang2006), but creation of selective ATP-competitive inhibitors for them is hardly possible due to the identity of the ATP binding sites. Different organisms also possess more than one GSK-3 isoform: for example, 4 homologues of GSK-3 were identified in Saccharomyces cerevisiae (Kassir et al. Reference Kassir, Rubin-Bejerano and Mandel-Gutfreund2006), and at least 15 isoforms are known for SHAGGY, a GSK-3 homologue from Drosophila melanogaster (Hoskins et al. Reference Hoskins, Carlson, Kennedy, Acevedo, Evans-Holm, Frise, Wan, Park, Mendez-Lago, Rossi, Villasante, Dimitri, Karpen and Celniker2007).
Glycogen synthase kinase 3 is a validated target for anti-protozoal drugs. It was shown that inhibitors of GSK-3 can be used against Plasmodium falciparum (Droucheau et al. Reference Droucheau, Primot, Thomas, Mattei, Knockaert, Richardson, Sallicandro, Alano, Jafarshad, Baratte, Kunick, Parzy, Pearl, Doerig and Meijer2004), Leishmania donovani (Xingi et al. Reference Xingi, Smirlis, Myrianthopoulos, Magiatis, Grant, Meijer, Mikros, Skaltsounis and Soteriadou2009), Toxoplasma gondii (Qin et al. Reference Qin, Tang and Kim1998) and Trypanosoma brucei (Ojo et al. Reference Ojo, Gillespie, Riechers, Napuli, Verlinde, Buckner, Gelb, Domostoj, Wells, Scheer, Wells and Van Voorhis2008); however, only well-known inhibitors of the human kinase were tested in these trials. Recently, a number of anti-malarial compounds were identified which inhibit the growth of P. falciparum, and many of them are known to inhibit human GSK-3 (Gamo et al. Reference Gamo, Sanz, Vidal, de Cozar, Alvarez, Lavandera, Vanderwall, Green, Kumar, Hasan, Brown, Peishoff, Cardon and Garcia-Bustos2010). Inhibition of GSK-3 was also studied during embryogenesis of ticks (Rhipicephalus (Boophilus) microplus) and was suggested as a possible tactic for tick control (Logullo et al. Reference Logullo, Witola, Andrade, Abreu, Gomes, da Silva Vaz, Imamura, Konnai, Ohashi and Onuma2009; Fabres et al. Reference Fabres, Pinto de Andrade, Guizzo, Sorgine, Paiva-Silva, Masuda, Da Silva Vaz and Logullo2010).
Homology modelling has previously been performed for protozoal kinases (Droucheau et al. Reference Droucheau, Primot, Thomas, Mattei, Knockaert, Richardson, Sallicandro, Alano, Jafarshad, Baratte, Kunick, Parzy, Pearl, Doerig and Meijer2004; Ojo et al. Reference Ojo, Gillespie, Riechers, Napuli, Verlinde, Buckner, Gelb, Domostoj, Wells, Scheer, Wells and Van Voorhis2008; Xingi et al. Reference Xingi, Smirlis, Myrianthopoulos, Magiatis, Grant, Meijer, Mikros, Skaltsounis and Soteriadou2009) with the aim of proposing the inhibitor binding mode. A P. falciparum GSK-3 model was also extensively analysed by Kruggel and Lemcke (Reference Kruggel and Lemcke2009a, Reference Kruggel and Lemckeb). Xiao et al. (Reference Xiao, Li, Sun, Zhang and Sun2004) performed a homology modelling and molecular dynamics study of Arabidopsis thaliana GSK-3/SHAGGY-like kinase, but that study is of limited relevance to the design of new anti-parasitic drugs. A direct comparison of GSK-3 models for various organisms, especially parasitic worms and fungi, and thorough sequence analysis has never been performed.
The main aim of this study was to analyse the possible application of GSK-3 inhibitors as selective anti-parasitic drugs. We have considered the selectivity issues based on amino acid composition of the ATP binding site and constructed molecular models of parasite GSK-3 enzymes.
MATERIALS AND METHODS
Sequence analysis and alignment
The amino acid sequences of the proteins under consideration (Table 1) were obtained from the PubMed Protein database. Catalytic domains were extracted according to annotation where possible, and in other cases were assigned by homology. Alignment of amino acid sequences (Fig. 2) was performed with ClustalX 2.0.11 (Larkin et al. Reference Larkin, Blackshields, Brown, Chenna, McGettigan, McWilliam, Valentin, Wallace, Wilm, Lopez, Thompson, Gibson and Higgins2007), manual adjustments were introduced where needed. Sequence identity was calculated with GENEDOC (Nicholas et al. Reference Nicholas, Nicholas and Deerfield II1997). A phylogenetic tree was built using the MEGA 4 program (Tamura et al. Reference Tamura, Dudley, Nei and Kumar2007) with the following parameters: Analysis – phylogeny reconstruction, Method – Neighbour-joining, Bootstrap – 1000 replicates, Model – p-distance.
Amino acid sequence alignment of the GSK-3s considered in this study. The background colour varies from the least conserved residues (white) to the most conserved residues (black).
GSK-3 sequences considered in this study
Molecular modelling
The modelling of protein structures was performed with Modeller 9v7 (Šali and Blundell, Reference Šali and Blundell1993). The X-ray structures of human GSK-3β complexed with indirubin inhibitors (PDB access codes 1UV5 (Meijer et al. 2003) and 1Q41, chain B (Bertrand et al. Reference Bertrand, Thieffine, Vulpetti, Cristiani, Valsasina, Knapp, Kalisz and Flocco2003)) were used as the templates for modelling, as it has been shown in previous studies that indirubins are equipotent inhibitors of the parasite and human kinases. For each target, 50 models were generated based on each template and optimized by Modeller's internal simulated annealing procedure (slow optimization of the model, 300 iterations of the conjugate gradient runs, very slow simulated annealing refinement, 3 repeats of the optimization cycle until objective function was >106). The best model was selected according to the DOPE score and objective function implemented in Modeller and the Procheck validation score (Laskowski et al. Reference Laskowski, MacArthur, Moss and Thornton1993), then models built based on each template were compared by Ramachandran plot parameters (Supplementary Table 1; Online version only). Interestingly, in all cases the best ranked model by all criteria was the same. Models based on the 1Q41 template gave better Ramachandran plot parameters consistently, so they were used for further consideration. Folding quality assessed with ProSA z-score (Sippl, Reference Sippl1993) was good for all models (Supplementary Table 1; Online version only). Comparison of the models was performed in SYBYL 8.0 (Tripos Inc., 1699 South Hanley Road, St Louis, Missouri, 63144, USA).
RESULTS
Amino acid sequence alignment and phylogeny
An alignment of amino acid sequences of glycogen synthase kinase homologues belonging to various species of mammals, insects, worms, fungi and protozoa was built (Fig. 2). Mammals and drosophila were used as references, and other organisms are either pathogenic or serve as transmitters of different diseases (e.g. A. aegypti or R. microplus). The sequence identity of catalytic domains was significant, the least similar to human GSK-3β being leishmanial kinases possessing 44% identity. The conserved regions and residues correspond to the standard GSK-3 catalytic domain; insertions and deletions are located mainly in the loop regions and do not affect the ATP-binding region, activation loop and priming site. The most notable exceptions are AtGSK-3 lacking the glycine loop (probably due to errors in genome annotation), and BmGSK-3 possessing the large deletions in the region between the activation loop and C-terminus that corresponds to the axin binding site; interestingly, the C-terminal region of BmGSK-3 is highly homologous to the respective part of HsGSK-3.
In most cases auto-inhibition of the kinase by the phosphorylated N-terminal domain is possible: these domains are long enough to interact with the priming phosphate binding site. Nevertheless, certain organisms such as leishmania or trypanosoma lack the N-terminal domain and consequently may not have this option. Worms and the majority of fungi have a rather short N-terminal sequence containing a putative phosphorylatable serine residue (e. g., Ser2, Ser10 and Ser11 of PbrGSK-3).
C-terminal domains of the studied kinases are of similar size. SHAGGY has the longest C-terminal domain, leishmanial and trypanosomial kinases lack the non-conserved part of the domain. Data on the function of this domain are scarce, and its further consideration would be overly speculative.
Many functionally important residues are conserved throughout the studied kinases. Apart from Lys85, Asn186, Asp200, and other residues crucial for kinase function which are characteristic for the whole protein kinase superfamily, residues forming the priming phosphate binding site (Arg96, Arg180, Lys205), affecting substrate binding (Phe67) and interacting with Tyr216 (Arg 220 and Arg223) are also present in all studied sequences. Certain residues lining the ATP-binding pocket are also identical for all GSK-3s: Gly63, Val70, Ala83, Pro136, Thr138, Leu188, and Cys199. The variable residues are described along with the models (see next section).
A phylogenetic tree of the GSK-3s corresponds to the phylogeny of the studied species (Supplementary Fig. 1; Online version only). Protozoal kinases form a distinct branch, and another branch is formed by metazoa. Fungal kinases comprise a separate branch from animal kinases. Mammalian kinases form 2 distinct groups corresponding to the α and β isoforms, other branches are formed by insect and worm kinases. Protozoa are characterized by the greatest diversity and distance from human kinases; for example, the distance between the plasmodial and leishmanial sequences is much larger than the distance between the human and insect kinases.
Modelling of the catalytic domains of the kinases
Overall characterization of the models
All models built possess good stereochemical quality. According to PROCHECK, no more than 2% of residues are located in the disallowed and generously allowed regions of the Ramachandran plot for each model that corresponds to the overall quality of the models. Due to significant similarity between the template and target sequences, root-mean-square deviation (rmsd) of the Cα atoms between the template and models is low and does not exceed 2·1 Å for any model except the model of TPK3 (rmsd 5·84 Å) (Fig. 3). The high rmsd of the latter model is due to the presence of the large insertions leading to the overall displacement of the backbone compared to the template.
The sequence length of the catalytic domain of mammalian and insect kinases is the same, except MmGSK-3α, which bears a single insertion N-terminal to H helix (Table 2). Insertions or deletions (indels) at this site are most abundant among studied kinases, but they are of no use for targeting selective inhibitors because this loop does not affect the enzyme function. The second site of frequent indels is located at the flexible loop β4–β5, which also cannot be used for inhibitor design.
Insertions and deletions in the catalytic domains of studied kinases relative to the human GSK-3 (see Fig. 3)
Insertions at the C helix observed in the leishmanial and trypanosomial kinases are more interesting since they can lead to substantial change of the kinase conformation near the binding site of non-competitive inhibitors (Martinez et al. Reference Martinez, Alonso, Castro, Dorronsoro, Gelpí, Luque, Pérez and Moreno2005; Ibrahim et al. Reference Ibrahim, Shilabin, Prasanna, Jacob, Khan, Doerksen and Hamann2008; Peng et al. Reference Peng, Kudrimoti, Prasanna, Odde, Doerksen, Pennaka, Choo, Rao, Tekwani, Madgula, Khan, Wang, Mayer, Jacob, Tu, Gertsch and Hamann2010). A similar effect may occur due to the presence of insertions at the αF-β7 loop, which are present in leishmanial kinases. Taken together, these differences near the phosphate-binding site may be explored in the design of new non-competitive inhibitors.
GSK-3 of C. neoformans has a unique large insertion in the β2–β3 loop, which can probably interact with the hinge region or change the flexibility of the glycine loop. As opposed to the other fungal kinases, this one does not have any deletions in the H helix region. Nevertheless, binding sites of the fungal kinases resemble each other closely (vide infra). The only exception is A. terreus GSK-3, which lacks the glycine loop forming the ‘ceiling’ of the binding site. Such a deletion should be non-functional due to the importance of the glycine loop for kinase activity and interaction with the substrate (Zhang et al. Reference Zhang, Jiang, Zou, Yu and Zhao2009b). Consequently, its presence could be explained by a gene sequencing or annotation inaccuracy.
B. malayi has a unique GSK-3 structure which lacks 2 large regions present in the other kinases under consideration. Firstly, residues 278–298, which form the outer wall of the axin binding site, are deleted (Dajani et al. Reference Dajani, Fraser, Roe, Yeo, Good, Thompson, Dale and Pearl2003). Secondly, a large deletion occurs between the activation loop and F helix. Nevertheless, the deletions do not affect the priming phosphate-binding site, Tyr216 and the ATP-binding site. Whilst seemingly not affecting the enzymatic function of GSK-3, they should, however, change the substrate selectivity profile of the kinase. Interestingly, helix G is conserved in BmGSK-3 and still can serve as a site of axin interaction despite the deletion of other axin-binding elements.
ATP-binding pocket
Despite the high similarity between the models, certain differences between the species do exist in the ATP-binding pocket that may affect the profile of the inhibitor selectivity. There are 8 such residues (Fig. 4): Ile62 (Val, Ala, Leu), Val110 (Ile, Ala), gatekeeper Leu132 (Met, Gln), Tyr134 (Phe, His, Leu), Val135 (Ile), Glu137 (Gln, Asp), Arg141 (Lys), and Gln185 (His). The conservation of gene sequence varies for these substitutions from very good (Gln185) to poor (Tyr134); conservation scores for variable residues as computed with ConSurf3.0 (Glaser et al. Reference Glaser, Pupko, Paz, Bell, Bechor, Martz and Ben-Tal2003; Landau et al. Reference Landau, Mayrose, Rosenberg, Glaser, Martz, Pupko and Ben-Tal2005; Ashkenazy et al. Reference Ashkenazy, Erez, Martz, Pupko and Ben-Tal2010) are given in Table 3.
Location of the insertions and deletions in the modelled kinases (coloured cyan) compared with the human GSK-3β (PDB access code 1Q41; coloured red, magenta and tan).
Frequency of appearance of certain residues in the binding site (%) and gene conservation scores
The residues of the ATP-binding pocket differ in their importance to inhibitor binding. For example, inhibitors can interact only with the backbone of Asp133, and mutations in this position should not affect inhibitor binding. A similar situation is observed for Tyr134: there are no inhibitors for which an interaction with the side-chain hydroxyl group has been shown, although such an interaction can appear in docking solutions (D. I. Osolodkin unpublished observation).
The binding pockets of insect and worm kinases are similar to those of mammalian kinases. The substitution Val135Ile appears in all studied cases and Arg141Lys is found in AaGSK-3 and SHAGGY. The former substitution does not change the physical properties of the binding site, but leads to a small decrease of the binding site volume. The latter substitution is functionally conserved: the Lys residue can form the same salt bridge with Glu137 as Arg, although the lysine residue is less conformationally restricted than arginine. SmGSK-3 also has a Tyr134Phe substitution, but its influence on inhibitor selectivity is minimal.
All fungal kinases have a valine residue instead of Ile62 that leads to easier entrance of ligands into the binding pocket due to its smaller volume. Most of them also have a Tyr134Phe substitution, and 2 species possess unique substitutions strongly affecting the selectivity of inhibitors: Val110Ala along with Ile62Val in CdGSK-3 opens the possibility of accepting significantly larger molecules than the human kinase does, and CgGSK-3 has a rare (Zuccotto et al. Reference Zuccotto, Ardini, Casale and Angiolini2010) glutamine residue in the gatekeeper position, the presence of which can be exploited in the design of selective inhibitors forming a hydrogen bond with the amide group.
The binding sites of protozoal kinases are the most diverged and the most diverse. The main difference between the human and protozoal GSK-3s is the substitution of the gatekeeper residue Leu132Met, which affects the volume of the binding site. Position 62 may be occupied by alanine (leishmania and trypanosoma), leucine (toxoplasma), or isoleucine (plasmodium). Plasmodium also has Ile residues in positions 110 and 135. The salt bridge between Arg141 and the residue in the position 137 (Glu or Asp) is possible in all cases except plasmodium, which possesses a Gln residue in position 137 and a Lys residue in the position 141. Nevertheless, leishmanial kinases lack this salt bridge due to the greater distance between Arg and Asp compared to Glu. Position 185 differs in leishmanial and trypanosomial kinases from the others: a histidine residue is present instead of glutamine.
DISCUSSION
Glycogen synthase kinase 3 is a functionally conserved enzyme among eukaryotes, whose 2 main functions are glucose metabolism and regulation of cell development and cell fate (Kassir et al. Reference Kassir, Rubin-Bejerano and Mandel-Gutfreund2006). Variability of the sequence is rather low and is mostly localized outside the core regions of the catalytic domain (Fig. 5). Specific features of this domain such as the priming phosphate-recognition site, phosphorylation site in the activation loop (Tyr216), and arginine residues which interact with the phosphorylated Tyr216, are present in all sequences.
Slight differences are observed in the ATP binding pockets of the modelled kinases. They do not seem to be crucial enough to define strict criteria of inhibitor selectivity, but are sufficient to achieve 10- to 30-fold selectivity of certain inhibitors between the human and parasite kinases (Droucheau et al. Reference Droucheau, Primot, Thomas, Mattei, Knockaert, Richardson, Sallicandro, Alano, Jafarshad, Baratte, Kunick, Parzy, Pearl, Doerig and Meijer2004; Ojo et al. Reference Ojo, Gillespie, Riechers, Napuli, Verlinde, Buckner, Gelb, Domostoj, Wells, Scheer, Wells and Van Voorhis2008; Xingi et al. Reference Xingi, Smirlis, Myrianthopoulos, Magiatis, Grant, Meijer, Mikros, Skaltsounis and Soteriadou2009). Paullones and indirubins are the most widely studied classes of GSK-3 inhibitors. Whereas indirubins are non-selective inhibitors and possess high affinity both to human and protozoal kinases, paullones bind 10- to 1000-fold tighter to human kinases than to protozoal. With the help of our models, it is possible to explain this fact. Firstly, paullones form only 2 hydrogen bonds with the hinge backbone, whereas indirubins form 3 (Bertrand et al. Reference Bertrand, Thieffine, Vulpetti, Cristiani, Valsasina, Knapp, Kalisz and Flocco2003), and this interaction is more favourable. Secondly, the methionine gatekeeper is longer and more flexible than the leucine one and can lead to steric complications during paullone binding (Kruggel and Lemcke, Reference Kruggel and Lemcke2009a). Additional steric clashes in the binding-site entrance may be introduced in plasmodial kinases by the Lys141 residue that is not restrained by a salt bridge and, moreover, can interact with the backbone carbonyl of residue 62 in a similar fashion to cyclin-dependent kinase 2 (Bhat et al. Reference Bhat, Xue, Berg, Hellberg, Ormö, Nilsson, Radesäter, Jerning, Markgren, Borgregård, Nylöf, Giménez-Cassina, Hernández, Lucas, Díaz-Nido and Avila2003). A similar situation can evolve in leishmanial kinases, which lack the salt bridge between Arg141 and Asp137 due to the shortness of the Asp side chain. Finally, the presence of 2 isoleucine residues instead of valines decreases the volume of the binding site and allows the acceptance of smaller inhibitors.
(a) Conservation of the ATP-binding pocket. Absolutely conserved residues and Asp133 are shown as sticks, variable residues – as balls-and-sticks. Colouring scheme is according to the conservation score (Table 3). (b) Variable residues of the binding pocket and neighbouring regions in the kinases under consideration. Colouring is according to the chemical properties of the residues (red on green – bulky lypophilic, red on dark green – small lypophilic, white on green – aromatic, green on red – acidic, white on red – basic, white on dark green – sulfur-containing, green on orange – amide-containing).
Fungal and worm glycogen synthase kinases 3 are more similar to human than to protozoal equivalents. The effects of their inhibition were not studied experimentally, but it is likely that GSK-3 also participates in pathways analogous to mammals and insects, for example, in glycogen metabolism or the Wnt pathway. Inhibition of GSK-3 leads to the failure of these pathways and should be lethal for simple organisms such as worms or fungi. Thus, new selective GSK-3 inhibitors could be used for treatment of fungal infections, schistosomosis and filariasis. Inhibitors of HsGSK-3 may be used as the starting scaffolds for the design of such inhibitors. Nevertheless, one should not exclude the possibility of preferential activation of Wnt pathway in special circumstances and subsequent activation of parasite growth.
Binding sites of the worm kinases contain only 1 significant substitution, Val135Ile, which leads to the slight decrease of the binding-site volume. Consequently, certain inhibitors of HsGSK-3 cannot inhibit worm kinases, but inhibitors of worm kinases could be able to inhibit the human enzyme.
The volume of the fungal kinases' binding site is larger than the volume of the HsGSK-3 binding site, and inhibitors of HsGSK-3 should also inhibit fungal ones. This could be a serious problem if the Wnt pathway is activated upon systemic GSK-3 inhibition due to the potentially rapid development of such fungal infections as candidosis during the treatment of type 2 diabetes (Chellan et al. Reference Chellan, Shivaprakash, Ramaiyar, Varma, Varma, Sukumaran, Vasukutty, Bal and Kumar2010). On the other hand, the development of selective inhibitors for certain fungi species or strains is possible due to the presence of specific substitutions. Further studies of the GSK-3 inhibitors' influence on fungi growth are needed to clarify this issue.
Certain guidelines for the design of selective GSK-3 inhibitors may be suggested based on our analysis. First of all, one should consider targeting the gatekeeper residue: compounds forming hydrogen bonds with the methionine sulphur atom should be selective for protozoal kinases over the human enzyme bearing the leucine gatekeeper. Highly selective inhibitors may be designed against CgGSK-3 targeting both the specific glutamine gatekeeper and larger binding pocket; other fungal kinases should accept inhibitors with larger hydrophobic substituents than the human kinase can accept. On the other hand, worm kinases may be selectively inhibited by smaller molecules than the human kinase inhibitors. Proper optimization of inhibitor shape is needed to achieve selectivity in this case.
CONCLUSIONS
We have performed the first direct comparison of the molecular models of glycogen synthase kinase-3 orthologues belonging to 21 parasitic organisms with human GSK-3. Despite the relatively high similarity between the ATP-binding pockets of human and non-human kinases revealed during this study, there are also certain differences sufficient to design selective inhibitors of parasite kinases. Inhibitors of the human kinase can also be used to treat parasites; at least, these inhibitors may be used as valuable starting points for rational design of novel anti-parasitic drugs.
ACKNOWLEDGEMENTS
The authors are thankful to Olga Bekker, Boris Nikashin, Liubov Kozlovskaya and Richard Claes for useful comments and suggestions.
FINANCIAL SUPPORT
This work was supported by the Russian Foundation for Basic Research (D. I. O. and V. A. P., grant number 08-03-00783), The Ministry of Education and Science of Russian Federation (D. I. O. and V. A. P., project number P-714), and by the RAS Presidium Program «From Fundamental Sciences to Medicine» (N. V. Z. and V. N. D.).
